Is SLXN or SRRK more undervalued in 2026?

CirclFi compares Silexion Therapeutics Corp (SLXN) and Scholar Rock Holding Corporatio (SRRK) using 13 institutional-grade valuation models. SLXN has a Quality of Company score of 5.3/10 while SRRK scores 5.1/10.

Which is a better buy — SLXN or SRRK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SLXN and SRRK valuations compare?

SLXN at $4.91 and SRRK at $49.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SLXN vs SRRK Valuation Comparison 2026 — Intrinsic Value Analysis

SLXN

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics Corp

Quality

5.3

out of 10

Value Trap

SAFE

Price

$4.91

Last close

Models

9/13

Active

SRRK

Biological Products, (No Diagnostic Substances)

Scholar Rock Holding Corporatio

Quality

5.1

out of 10

Value Trap

LOW

Price

$49.30

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	SLXN Fair Value	SLXN Upside	SRRK Fair Value	SRRK Upside
Bayesian DCF	Intrinsic	$0.41	-91.6%	$15.50	-68.6%
Earnings Power Value	Intrinsic	—	—	$21.36	-54.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.55	-68.4%	$4.25	-91.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLXN vs SRRK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLXN vs SRRK — Which Stock Is More Undervalued?

SLXN scores higher with a 5.3/10 quality rating vs SRRK's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Silexion Therapeutics Corp (SLXN) and Scholar Rock Holding Corporatio (SRRK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLXN currently trades at $4.91 with a QOC of 5.3/10, while SRRK trades at $49.30 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).